Table 4.
Treatment outcomes of HMT according to miR-22 expression status.
| Variables | Low miR-22 Expression (n = 26) |
High miR-22 Expression (n = 15) |
p-Value |
|---|---|---|---|
| Any response to HMT | 21 (80.8) | 13 (86.7) | 1.000 |
| Hematologic improvement | |||
|
15 (57.7) | 11 (73.3) | 0.317 |
|
17 (65.4) | 9 (60.0) | 0.730 |
| Disease progression | 16 (61.5) | 6 (40.0) | 0.183 |
| Median time to progression (m) * | 23.1 (5.5–67.1) | 25.9 (6.7–95.9) | 0.155 |
| Leukemic transformation | 15 (57.7) | 4 (26.7) | 0.055 |
| Death | 19 (73.1) | 8 (53.3) | 0.199 |
Abbreviations: HMT, hypomethylating therapy; m, month. * Median time to progression was calculated with the Kaplan–Meier method using intention-to-treat (ITT) analysis. A log-rank test was used to compare TTP.